Krystal Biotech Inc

$180.07
(as of Mar 31, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Krystal Biotech Inc

Stock Price
$180.07
Ticker Symbol
KRYS
Exchange
NASDAQ

Industry Information for Krystal Biotech Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Krystal Biotech Inc

Website
https://www.krystalbio.com
Country
USA
Full Time Employees
275

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Fundamentals for Krystal Biotech Inc

Market Capitalization
$5,298,017,792
EBITDA
$105,662,000
Dividends per Share
P/E Ratio
61.31
Forward P/E Ratio
24.45
Earnings per Share
$3
Earnings per Share Estimate Next Year
Profit Margin
30.69%
Shares Outstanding
28,806,100
Percent Owned by Insiders
12.24%
Percent Owned by Institutions
105.95%
52-Week High
52-Week Low

Technical Indicators for Krystal Biotech Inc

50-Day Moving Average
200-Day Moving Average
RSI
53.3
ATR
7.34

Analyst Ratings for Krystal Biotech Inc

Strong Buy
8
Buy
2
Hold
1
Sell
0
Strong Sell
0

News About Krystal Biotech Inc

Mar 28, 2025, 11:30 AM EST
It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. See more.
Mar 25, 2025, 1:08 PM EST
The United States market has shown a positive trend, rising 1.8% over the last week and 10% over the past year, with earnings projected to grow by 14% annually. See more.
Mar 21, 2025, 1:05 PM EST
As the U.S. stock market shows signs of stabilizing with the S&P 500 and Nasdaq attempting to break their recent losing streaks, investors are keenly observing companies that demonstrate resilience and potential for growth amid economic uncertainties. See more.
Mar 21, 2025, 11:30 AM EST
It has been about a month since the last earnings report for Krystal Biotech, Inc. See more.